SCHEMBL4641881

SCHEMBL4641881

CS(=O)(=O)Nc1ccc(I)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.41
TSHR P16473 1/20 0.41
MCL1 Q07820 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
CCR2 P41597 1/20 0.41
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
TNIK Q9UKE5 1/20 0.39
EP300 Q09472 1/20 0.39
KAT2B Q92831 1/20 0.39
KAT8 Q9H7Z6 1/20 0.39
MAP2K1 Q02750 1/20 0.38
KEAP1 Q14145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14906059 0.81 MCL1 (0.61) HPGDTSHRMCL1CCR2GAA
SCHEMBL9048534 0.79 MEN1 (0.50) HPGDTSHRMCL1KEAP1NFE2L2
SCHEMBL3781788 0.79 HPGD (0.55) HPGDGAAMAPK1CA1CA2
SCHEMBL6816106 0.79 CYP3A4 (0.48) HPGDTSHRMCL1GAAPIK3CD
SCHEMBL11560825 0.79 MCL1 (0.59) HPGDTSHRMCL1CCR2GAA
SCHEMBL13337358 0.78 ALDH1A1 (0.51) HPGDTSHRMCL1MAPK1PTGS1
SCHEMBL1542413 0.78 MAP2K1 (0.43) MAP2K1
SCHEMBL16492686 0.78 KMT2A (0.55) TSHRCCR2PIK3CDPIK3CAPIK3CB
SCHEMBL24481324 0.75 L3MBTL1 (0.46) CCR2
SCHEMBL22251740 0.75 PTGS2 (0.40) HPGDTSHRMCL1PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1824837-B1 SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS PFIZER (US) 2008-08-13 EP disclosed
US-7214824-B2 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists PFIZER INC. (US) 2007-05-08 US disclosed
US-20060100460-A1 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists PFIZER, INC. 2006-05-11 US disclosed
US-5258399-A 5-lipoxygenase inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-11-02 US disclosed
US-5236948-A Lipoxygenase inhibitor IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-17 US disclosed
EP-0495594-A1 Sulphonamide derivatives ZENECA LIMITED (GB) 1992-07-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100460-A1 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists CNR1, AVPR1A, OPRL1 HPGD 2915/4885TSHR 389/4885MCL1 2085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.